Table 2 Descriptive data for all 55 included studies
From: Association of saturated fatty acids with cancer risk: a systematic review and meta-analysis
Author, year | Country | Study design | Cancer | SFAs test source | Case | Control/Noncase | ||
|---|---|---|---|---|---|---|---|---|
Numbers (M/F) | Age (y) mean ± SD or min-max | Numbers (M/F) | Age (y) mean ± SD or min-max | |||||
Wu et al. (2023) [51] | China | Case-Control | Colorectal | Blood | 680 (350/330) | 53.69 ± 10.71 | 680 (344/336) | 53.25 ± 10.60 |
Nkondjock et al. (2003) [15] | Canada | Case-Control | Colorectal | Dietary Intake | 402 (200/202) | 20–79 | 668 (239/449) | 20–79 |
Mozafarinia et al. (2021) [16] | Iran | Case-Control | Breast | Dietary Intake | 473 (0/473) | 45.8 ± 10.3 | 501 (0/501) | 43.9 ± 11.2 |
Seyyedsalehi et al. (2022) [17] | Iran | Case-Control | Colorectal | Dietary Intake | 865 | 58.5 | 3206 | 57.1 |
Fan et al. (2022) [18] | China | Case-Control | Oral | Dietary Intake | 446 (258/188) | ≥ 18 | 448 (213/235) | ≥ 18 |
Tu et al. (2022) [19] | China | Case-Control | Colorectal | Dietary Intake | 2806 (1606/1200) | 57.11 ± 10.28 | 2806 (1606/1200) | 57.06 ± 9.90 |
Cai et al. (2020) [53] | Japan | Cohort | Lung | Dietary Intake | 1315 (901/414) | 45–74 | 71872 (32033/39839) | 45–74 |
Shimomura et al. (2022) [54] | Japan | Cohort | Non-Hodgkin Lymphoma | Dietary Intake | 230 | 49–64 | 93136 | 49–64 |
Takata et al. (2009) [20] | USA | Case-Control | Breast | Blood | 130 (0/130) | 58.6 ± 5.1 | 257 (0/257) | 58.6 ± 5.4 |
Chun et al. (2015) [21] | Korea | Case-Control | Colorectal | Dietary Intake | 150 (94/56) | 20–79 | 116 (71/45) | 20–79 |
Jackson et al. (2012) [22] | Jamaica | Case-Control | Prostate | Blood | 209 (209/0) | 67.5 ± 7.9 | 226 (226/0) | 62.6 ± 10.5 |
Chavarro et al. (2013) [23] | USA | Case-Control | Prostate | Blood | 476 (0/476) | 58 ± 8.1793 | 476 (0/476) | 58 ± 7.4358 |
Nkondjock et al. (2003) [24] | Canada | Case-Control | Breast | Dietary Intake | 414 | 55.0 ± 11.87 | 429 | 55.7 ± 12.18 |
Pan et al. (2004) [25] | Canada | Case-Control | Ovarian | Dietary Intake | 442 (0/442) | 55.1 ± 12.3 | 2135 (0/2135) | 55.2 ± 12.5 |
Shishavan et al. (2020) [26] | Iran | Case-Control | Pancreatic | Blood | 51 (26/25) | 58.59 ± 9.23 | 152 (79/73) | 58.22 ± 9.05 |
Matta et al. (2022) [27] | USA | Case-Control | Breast | Blood | 905 | 68.2 ± 5.7 | 1813 | 68.2 ± 5.7 |
Matejcic et al. (2018) [28] | Denmark France Greece Germany Italy Netherlands Norway Spain Sweden UK | Case-Control | Pancreatic | Blood | 375 (153/222) | 64.59 ± 8.87 | 375 (153/222) | 57.44 ± 8.28 |
Gilsing et al. (2011) [55] | Netherlands | Cohort | Ovarian | Dietary Intake | 340 | 61.8 ± 4.3 | 2161 | 61.4 ± 4.3 |
Kurahashi et al. (2008) [56] | Japan | Cohort | Prostate | Dietary Intake | 329 | 45–74 | 43106 | 45–74 |
Vlajinac et al. (1997) [29] | Serbia | Case-Control | Prostate | Dietary Intake | 101 (101/0) | 70.5 | 202 (202/0) | 71.5 |
Hodge et al. (2015) [57] | Italy Greek | Cohort | Colorectal | Dietary Intake Blood | 395 (197/198) | 61.4 ± 8.1 | 3810 (1697/2113) | 54.3 ± 11.1 |
Lof et al. (2007) [58] | Sweden | Cohort | Breast | Dietary Intake | 974 (0/974) | 39 ± 3 | 43595 (0/43595) | 39 ± 3 |
Knekt et al. (1990) [59] | Finland | Cohort | Breast | Dietary Intake | 54 (0/54) | 47.2 ± 12.4 | 3934 (0/3934) | 41.1 ± 13.7 |
Thiébaut et al. (2009) [60] | USA | Cohort | Pancreatic | Dietary Intake | 1337 (865/472) | 50–71 | 524136 (307871/216265) | 50–71 |
Kraja et al. (2015) [61] | Netherlands | Cohort | Colorectal | Dietary Intake | 222 (97/125) | ≥ 55 | 4754 | ≥ 55 |
Aglago et al. (2021) [62] | Denmark France Greece Germany Italy Netherlands Norway Spain Sweden UK | Cohort | Colorectal | Dietary Intake Blood | 6162 (43%/57%) | 57.1 ± 7.79 | 443950 (29%/71%) | 51.0 ± 9.75 |
Shishavan et al. (2021) [63] | Iran | Cohort | Pancreatic | Dietary Intake | 76 (41/35) | 58.11 ± 9.49 | 46904 (19562/27342) | 51.83 ± 8.80 |
Zhu et al. (2019) [30] | China | Case-Control | Stomach | Dietary Intake | 1900 (1401/499) | 64.1 ± 10.8 | 6532(4713/1819) | 64.0 ± 11.3 |
Sczaniecka et al. (2012) [64] | USA | Cohort | Breast | Dietary Intake | 772 | 50–76 | 29480 | 50–76 |
Wakai et al. (2005) [65] | Japan | Cohort | Breast | Dietary Intake | 129 | 40–79 | 26162 | 40–79 |
Shannon et al. (2007) [31] | China | Case-Control | Breast | Blood | 330 | ≥35 | 1038 | ≥35 |
Hirko et al. (2018) [32] | USA | Case-Control | Breast | Blood | 794 | 44.7 (4.5) | 794 | 44.8 (4.4) |
Crowe et al. (2008) [33] | Denmark Germany Greece Italy Netherlands Spain Sweden UK | Case-Control | Prostate | Blood | 962 | 60.4 ± 5.8 | 1061 | 60.1 ± 5.7 |
Wakai et al. (2000) [34] | Japan | Case-Control | Bladder | Dietary Intake | 300 (243/57) | 20–99 | 300 (243/57) | 20–99 |
Bravi et al. (2013) [35] | Italy Switzerland | Case-Control | Oral and Pharyngeal | Dietary Intake | 768 (593/175) | 58 (22–79) | 2078 (1368/710) | 59 (19–79) |
Challier et al. (1998) [36] | French | Case-Control | Breast | Dietary Intake | 345 | 30–78 | 345 | 30–78 (± 13 years) |
Voorrips et al. (2002) [66] | Netherlands | Cohort | Breast | Dietary Intake | 941 | 55–69 | 1598 | 55–69 |
Do et al. (2003) [37] | Korean | Case-Control | Breast | Dietary Intake | 224 | 20–69 | 250 | 20–69 |
Gong et al. (2010) [38] | USA | Case-Control | Pancreatic | Dietary Intake | 532 (291/241) | 21–85 | 1701 (883/818) | 21–85 |
Lucenteforte et al. (2008) [39] | Italy | Case-Control | Endometrial | Dietary Intake | 454 | 60 (18–79) | 908 | 61 (19–79) |
Lucenteforte et al. (2009) [40] | Italy | Case-Control | Stomach | Dietary Intake | 230 (143/87) | 63 (22–80) | 547 (286/261) | 63 (22–80) |
Lucenteforte et al. (2010) [41] | Italy | Case-Control | Pancreatic | Dietary Intake | 326 (174/152) | 63 (34–80) | 652 (348/304) | 63 (34–80) |
Bidoli et al. (2008) [42] | Italy | Case-Control | Renal Cell | Dietary Intake | 767 (494/273) | 62 (24–79) | 1534 (988/546) | 62 (22–79) |
Jessri et al. (2011) [43] | Iran | Case-Control | Esophageal Cquamous Cell Carcinoma | Dietary Intake | 47 (18/29) | 40–75 | 96 (38/58) | 40–75 |
Bidoli et al. (2002) [44] | Iran | Case-Control | Ovarian | Dietary Intake | 1031 | 56 (18–79) | 2411 | 57 (17–79) |
Polesel et al. (2007) [45] | Italy | Case-Control | Hepatocellular carcinoma | Dietary Intake | 185 (149/36) | 66 (43–84) | 412 (281/131) | 65 (40–82) |
Bassett et al. (2013) [46] | Australia | Case-Control | Prostate | Dietary Intake Blood | 464 | 62.7 ± 6.0 | 1661 | 54.1 ± 11.4 |
Pouchieu et al. (2014) [47] | UK | Case-Control | Overall | Blood | 250 (80/170) | 51.0 ± 6.0 | 250 (80/170) | 51.3 ± 6.2 |
Wise et al. (2014) [67] | USA | Cohort | Uterine Leiomyomata | Dietary Intake | 2695 | 21–69 | 9349 | 21–69 |
Luu et al. (2018) [68] | China | Cohort | Lung | Dietary Intake | 1496 | Female: 40–70 Male: 40–74 | 120474 | Female: 40–70 Male: 40–74 |
Kuriki et al. (2006) [48] | Japan | Case-Control | Colorectal | Blood | 74 (45/29) | 58.4 ± 9.6 | 221 (134/87) | 58.0 ± 9.6 |
Sellem et al. (2018) [9] | French | Cohort | Overall | Dietary Intake | 1722 | 56.9 ± 7.4 | 42317 | 56.9 ± 7.4 |
Saadatian-Elahi et al. (2002) [49] | USA | Case-Control | Breast | Blood | 197 | 34–65 | 197 | 34–65 |
Vinceti et al. (2013) [50] | Italy | Case-Control | Cutaneous Melanoma | Blood | 51 (23/28) | 25–79 | 51 (23/28) | 25–79 |
Nkondjock et al. (2005) [52] | Canada | Case-Control | Pancreatic | Dietary Intake | 462 (258/204) | 30–74 | 4721 (2331/2309) | 30–74 |